针对神素1-酸盐代谢作为前列腺癌的治疗途径
Saida Mebarek1, Najwa Skafi2, Leyre Brizuela1
1CNRS UMR 5246, INSA Lyon, Institut de Chimie et Biochimie Moléculaires et Supramoléculaires (ICBMS), 69622 Lyon, France.
Cancers
|June 22, 2023
概括
本综述强调了神素1-酸盐 (S1P) 代谢在前列腺癌 (PC) 进展和治疗耐药性的作用. 针对S1P途径为高级PC提供了一个有前途的治疗策略.
科学领域:
- 在瘤学瘤学.
- 生物化学 生化学
- 脂质代谢 脂质代谢是什么
背景情况:
- 前列腺癌 (PC) 是男性癌症死亡的主要原因,转移性疾病是无法治愈的.
- 氨酸1-酸盐 (S1P) 是一种生物活性脂质,涉及癌细胞的增殖,生存,迁移,入侵和转移.
- S1P代谢的调节失调,涉及基酶 (SK1/SK2) 和S1P溶酶 (SPL),与PC发育和治疗耐药性有关.
研究的目的:
- 审查关于S1P及其代谢伙伴在前列腺癌中的作用的关键研究.
- 要突出用于研究PC中S1P代谢的各种体外,体外和体内模型.
- 在PC治疗的临床前和临床开发中总结了针对S1P代谢的分子.
主要方法:
- 使用PubMed的文献综述,关键词包括"前列腺和脊髓","前列腺癌骨转移"和"前列腺癌治疗".
- 专注于最近的审查,以涵盖PC和脂代谢.
- 分析表明S1P代谢对PC进展和治疗耐药性的研究.
主要成果:
- S1P信号及其代谢酶 (SK1,SK2,SPL) 在PC瘤发生,进展和对治疗的耐药性方面至关重要.
- 各种实验模型已经证实了S1P代谢在PC中的参与.
- 针对S1P代谢的几个分子正在临床前和临床开发中.
结论:
- S1P代谢是前列腺癌进展和治疗结果的重要因素.
- 针对单独或与其他疗法结合的S1P代谢,为PC患者提供了潜在的未来治疗策略.
- 为了有效的PC管理,需要对S1P向剂进行进一步的研究和临床开发.
相关概念视频
02:57Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
01:27Transducer Mechanism: Enzyme-Linked Receptors
2.5K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.5K
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
221
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
221
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
197
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
197